William O’Riordan

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.9K citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton et al. · New England Journal of Medicine · 2021 · 495 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +10

The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison

David G. Sherman, Gregory W. Albers, Christopher Bladin et al. · The Lancet · 2007 · 332 citations

Medicine, Hematology, Pharmacotherapy +16

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

G. Ralph Corey, Heidi Kabler, Purvi Mehra et al. · New England Journal of Medicine · 2014 · 302 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

Martín E. Stryjewski, Donald R. Graham, Samuel E. Wilson et al. · Clinical Infectious Diseases · 2008 · 289 citations

Pharmacy, Infectious Diseases, Pharmacology +17